PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11787334

[Spasticity and multiple sclerosis].

B Bussel·O R Neris·L Mailhan
View original source ↗Export metadata ↓

Abstract

Spasticity is a common symptom in MS patients. It is easy to recognize and evaluate spasticity at rest. The efficacy of numerous treatments has been well documented. Nevertheless, it is difficult, particularly in MS patients, to assess the functional disability due to spasticity and the functional benefit due to treatment. This is why it is appears more appropriate to use therapeutic tests with transitory effects such as anesthetic blocks in case of focal spasticity or intrathetical baclofen in case of diffuse spasticity. It is also possible to use reversible treatments such as botulinum toxin injections before proposing section of a peripheral nerve.

Explore related subjects

Disability EvaluationHumansMultiple SclerosisMuscle SpasticityNeurologic ExaminationNeuromuscular AgentsPrognosisTreatment OutcomeEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Bussel, O R Neris, L Mailhan. 2001. [Spasticity and multiple sclerosis].. https://pubmed.ncbi.nlm.nih.gov/11787334/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

[Significance of environmental medicine from the viewpoint of the medical review board of the social health insurance program].

Tasks concerning environmental medicine are a significant aspect of the expert work done by the medical review board of the social health insurance fund. Thus far there are no commonly accepted theories and/or criteria with regard to the cause of environmental incompatibilities, nor are there generally accepted criteria/standards for clinical diagnostic procedures and therapy. Problems arise from the fact that the field of environmental medicine not only offers scientifically accepted and verified diagnostic and therapeutic methods, but also numerous unconventional procedures without verified validity. The decision of the scientific expert has to be based on the legal principles of social legislation and jurisdiction. His/her opinion must be competent, objective and independent. Further research is urgently needed to improve the scientific data pool. With it, well-grounded methods and standards can be offered.

Disability Evaluation↗
PubMed2003

Mitoxantrone in progressive multiple sclerosis: when and how to treat?

Mitoxantrone (MX) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with worsening relapsing-remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). However, indications should be refined and mitoxantrone reserved as a rescue therapy to: (1) patients in the relapsing-remitting phase with frequent and disabling exacerbations likely leading to permanent severe disability and (2) to patients in the secondary progressive phase whose disability progression rate increases by one EDSS point or more per year and who do not respond to other current therapies. An induction phase with the monthly intravenous administration of 12 mg/m(2) followed by a maintenance phase with 12 mg/m(2) every 3 months for 2 years seems the most effective and safe treatment regimen, not exceeding the maximum cumulative dose of 140 mg/m(2). Given the potent myelosuppressive activity of mitoxantrone, dosage should be carefully adapted to the body surface and hematological changes. Long-term toxicities (amenorrhoea and therapy-related leukemia) seem acceptable but a valid evaluation will need a longer follow-up in more patients. Cardiotoxicity, the major long-term toxicity, is clearly dose-dependent and is a strict treatment duration limiting factor. To reduce the risk of cardiac events, the drug should be administered by slow infusion (over 30 min). Analogs of mitoxantrone with a much lower cardiotoxicity are currently investigated in animal experimental models.

Disability Evaluation↗